New ultrasound device could spot liver disease early and speed up specialist care

NCT ID NCT06387745

Recruiting now Diagnosis Sponsor: University Hospital, Antwerp Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new, non-invasive ultrasound device called the Hepatoscope to screen for liver scarring (fibrosis) and fatty liver in people at risk. Researchers will enroll 200 patients with risk factors like diabetes or elevated liver enzymes. Those with high stiffness readings on the scan will be referred to a liver specialist, and the device's accuracy will be compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hepatoscope (non-invasive ultrasound device)
What this could lead to: If successful, this could provide a simple, non-invasive way to identify patients who need specialist care for chronic liver disease, potentially catching problems earlier.
What could go wrong: This is an early-stage diagnostic study with 200 participants, so results may not apply to everyone. The device's accuracy compared to standard tests is still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fibrotic liver disease liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LIVER DISEASE

Contacts and locations

Locations

Universitair Ziekenhuis Antwerpen
RECRUITING

Edegem, Antwerp, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.